Julia E Maxson Selected Research

BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative)

1/2020	Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
2/2016	The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
1/2014	Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
9/2013	The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Julia E Maxson Research Topics

Disease

9	Chronic Neutrophilic Leukemia 11/2022 - 09/2013
8	Leukemia 01/2022 - 05/2013
7	Neoplasms (Cancer) 01/2021 - 09/2013
6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 06/2015
4	BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative) 01/2020 - 09/2013
2	Inflammation (Inflammations) 09/2013 - 10/2012
1	Myeloid Leukemia (Leukemia, Myelocytic) 12/2021
1	Philadelphia Chromosome 01/2021
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021
1	Disease Progression 01/2021
1	Hematologic Neoplasms (Hematological Malignancy) 12/2019
1	Juvenile Myelomonocytic Leukemia 01/2018
1	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2016
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 06/2015
1	Hypersensitivity (Allergy) 02/2014
1	Myeloproliferative Disorders (Myeloproliferative Disorder) 11/2013
1	Atrophy 09/2013
1	Cachexia 09/2013
1	Body Weight (Weight, Body) 10/2012

Drug/Important Bio-Agent (IBA)

5	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 11/2022 - 01/2014
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021 - 05/2013
3	Phosphotransferases (Kinase)IBA 01/2021 - 05/2013
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2019 - 09/2013
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2020
2	ruxolitinibIBA 01/2020 - 01/2020
2	LigandsIBA 12/2018 - 02/2014
1	Carrier Proteins (Binding Protein)IBA 12/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	UbiquitinIBA 01/2021
1	Lysine (L-Lysine)FDA Link 01/2020
1	RNA (Ribonucleic Acid)IBA 12/2019
1	Transcription Factors (Transcription Factor)IBA 11/2019
1	Protein Tyrosine PhosphatasesIBA 01/2018
1	Anaplastic Lymphoma KinaseIBA 06/2015
1	Janus Kinase InhibitorsIBA 11/2013
1	GlucocorticoidsIBA 09/2013
1	Myeloid Differentiation Factor 88IBA 09/2013
1	EndotoxinsIBA 09/2013
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 09/2013
1	Proteins (Proteins, Gene)FDA Link 09/2013
1	LipopolysaccharidesIBA 10/2012

Therapy/Procedure

3	Therapeutics 01/2022 - 06/2015
1	Precision Medicine 01/2016
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 11/2013
1	Aftercare (After-Treatment) 10/2012